Charles River Laboratories (CRL) Tops Q2 EPS by 7c, Updates Guidance
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $469.1 million versus the consensus estimate of $458.03 million.
GUIDANCE:
Charles River Laboratories sees FY2017 EPS of $5.00-$5.15, versus the consensus of $5.10.
| 2017 GUIDANCE (from continuing operations) | REVISED | PRIOR | ||||||
| Revenue growth, reported | 8.5% - 10.0% | 7.5% - 9.0% | ||||||
| Less: Contribution from acquisitions (1) | (~5.0% - 6.0%) | (~5.0% - 6.0%) | ||||||
| Add: Effect of CDMO divestiture | ~1.0% | ~1.0% | ||||||
| Add: Negative effect of 53rd week in 2016 | ~1.5% | ~1.5% | ||||||
| Add: Negative effect of foreign exchange | ~1.0% | ~2.0% - 2.5% | ||||||
| Revenue growth, organic (2) | 7.0% - 8.5% | 7.0% - 8.5% | ||||||
| GAAP EPS estimate | $4.18-$4.33 | $4.18-$4.33 | ||||||
| Amortization of intangible assets (3) | ~$0.58 | ~$0.58 | ||||||
| Charges related to global efficiency initiatives (4) | ~$0.02 | ~$0.02 | ||||||
| Acquisition/divestiture-related adjustments (5) | ~$0.07 | ~$0.07 | ||||||
| Net impact of CDMO divestiture (6) | ~$0.15 | ~$0.15 | ||||||
| Non-GAAP EPS estimate | $5.00- $5.15 | $5.00 - $5.15 | ||||||
Footnotes to Guidance Table
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.